低血清激肽释放酶结合蛋白水平与院外心脏骤停幸存者不良神经结局相关:蛋白质组学研究
该研究纳入7名健康志愿者和34名入住ICU并接受目标温度管理的院外心脏骤停幸存者,按6个月脑功能分类(CPC)量表分为良好结局组(CPC 1-2)和不良结局组(CPC 3-5),在入住ICU后0、24、72小时采集血样。采用蛋白质组学方法从7组混合血清中筛选出23种组间差异蛋白,进一步选择7种在良好与不良结局组间强度差异大于2倍的候选蛋白,排除5种与溶血或高丰度残留相关的蛋白。用酶联免疫吸附测定验证视网膜脱氢酶1和激肽释放酶结合蛋白,最终发现高龄(OR=1.055;95%CI 1.002-1.112;P=0.043)和0小时低血清激肽释放酶结合蛋白水平(OR=0.784;95%CI 0.618-0.995;P=0.046)与6个月不良神经结局独立相关。结论认为入住ICU时血清激肽释放酶结合蛋白耗竭与院外心脏骤停幸存者不良神经结局相关。
要点
- 34名院外心脏骤停幸存者入住ICU并接受目标温度管理,按6个月CPC分为良好组(CPC 1-2)和不良组(CPC 3-5)。
- 0小时低血清激肽释放酶结合蛋白水平与6个月不良神经结局独立相关(OR=0.784;95%CI 0.618-0.995;P=0.046)。
- 高龄与6个月不良神经结局独立相关(OR=1.055;95%CI 1.002-1.112;P=0.043)。
- 蛋白质组学从7组混合血清中筛出23种组间差异蛋白,选7种候选(良好与不良组间差异大于2倍),排除5种溶血或高丰度残留相关蛋白后验证2种。
- 该关联为观察性研究结果,尚未证明血清激肽释放酶结合蛋白可用于床旁预测或干预。
适用人群与场景
- 7名健康志愿者和34名入住ICU并接受目标温度管理的院外心脏骤停幸存者。
- 按6个月脑功能分类(CPC)量表分为良好结局组(CPC 1-2)和不良结局组(CPC 3-5)。
诊断标准与关键阈值
- 6个月神经结局采用脑功能分类(CPC)量表评估:CPC 1-2为良好结局,CPC 3-5为不良结局。
研究设计与关键结果
- 研究类型为蛋白质组学研究,纳入7名健康志愿者和34名院外心脏骤停幸存者,在入住ICU后0、24、72小时采集血样。
- 蛋白质组学方法发现23种蛋白在7组混合血清(健康志愿者、良好结局组0/24/72小时、不良结局组0/24/72小时)间存在组间差异。
- 选择7种在良好与不良结局组间强度差异大于2倍的候选蛋白,排除5种与溶血或高丰度残留相关的蛋白,用酶联免疫吸附测定验证视网膜脱氢酶1和激肽释放酶结合蛋白。
- 多因素分析显示高龄(OR=1.055;95%CI 1.002-1.112;P=0.043)和0小时低血清激肽释放酶结合蛋白水平(OR=0.784;95%CI 0.618-0.995;P=0.046)与6个月不良神经结局独立相关。
证据类型、等级与局限
- 证据类型:蛋白质组学研究(观察性关联分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论认为入住ICU时血清激肽释放酶结合蛋白耗竭与院外心脏骤停幸存者不良神经结局相关;原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM OF THE STUDY: To identify proteins of which depletion are associated with the poor 6-month neurological outcome of out-of-hospital cardiac arrest survivors.
METHODS: Seven healthy volunteers and 34 out-of-hospital cardiac arrest survivors admitted to the intensive care unit (ICU) and underwent targeted-temperature management were enrolled. According to the 6-month cerebral performance category (CPC) scale, patients were divided into the good (CPC 1-2) and poor (CPC 3-5) outcome groups. Blood samples were obtained at 0, 24, and 72 h after admission to the ICU.
RESULTS: With proteomic approaches, we found 23 proteins that showed group-differences between the sera pooled from 7 study groups: healthy volunteers, the good outcome groups (0, 24, and 72 h), and the poor outcome groups (0, 24, and 72 h). We selected 7 candidate proteins of which intensities were different between the good and poor outcome groups (>2-fold change) and excluded 5 proteins related to haemolysis or remaining high abundant proteins. To confirm the 2 identified proteins: retinal dehydrogenase 1 and Kallistatin, we performed enzyme-linked immunosorbent assay with individual serum. Finally, old age (odds ratio = 1.055; 95% confidence interval, 1.002-1.112; p = 0.043) and low serum kallistatin level at 0 h (odds ratio = 0.784; 95% confidence interval, 0.618-0.995; p = 0.046) were independently associated with the poor 6-month neurological outcome.
CONCLUSION: The depletion of serum kallistatin at admission to the ICU was associated with the poor neurological outcome of out-of-hospital cardiac arrest survivors.
参考来源
- Jung YS, Kwon WY, Suh GJ, et al. Low serum Kallistatin level was associated with poor neurological outcome of out-of-hospital cardiac arrest survivors: Proteomics study. Resuscitation. 2018. PMID: 29698750. doi:10.1016/j.resuscitation.2018.04.025
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。